XML 43 R30.htm IDEA: XBRL DOCUMENT v3.26.1
Revenue Recognition (Tables)
 3 Months Ended
Mar. 31, 2026
Revenue from Contract with Customer [Abstract]  
Schedule of Disaggregation of Revenue
The following table represents Evolent’s revenue disaggregated by line of business and product type (in thousands):
For the Three Months Ended March 31,
20262025
Medicaid$218,114 $188,124 
Medicare162,810 115,318 
Commercial and other115,322 180,207 
Total$496,246 $483,649 
Performance Suite (1)
$323,303 $303,021 
Specialty Technology and Services Suite80,799 82,821 
Administrative Services49,587 57,191 
Cases42,557 40,616 
Total$496,246 $483,649 
————————
(1)Performance Suite revenue includes $323.3 million and $245.2 million related to our specialty care management solution for the three months ended March 31, 2026 and 2025, respectively.
Schedule of Contract with Customer, Asset and Liability
The following table provides information about receivables, contract assets and deferred revenue from contracts with customers (in thousands):
March 31, 2026December 31, 2025
Short-term receivables (1)
$312,521 $307,423 
Short-term deferred revenue1,417 1,203 
Long-term deferred revenue— 110 
————————
(1)Excludes pharmacy rebate receivable and pharmacy claims receivable.

Changes in deferred revenue the three months ended March 31, 2026 are as follows (in thousands):
Deferred revenue
Balance as of beginning-of-period$1,313 
Reclassification to revenue, as a result of performance obligations satisfied(614)
Cash received in advance of satisfaction of performance obligations718 
Balance as of end of period$1,417